Dogwood Therapeutics, Inc. (NASDAQ:DWTX – Free Report) – Stock analysts at Zacks Small Cap upped their Q3 2024 earnings estimates for shares of Dogwood Therapeutics in a research report issued on Monday, October 14th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($1.40) per share for the quarter, up from their previous forecast of ($1.50). The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($5.50) per share. Zacks Small Cap also issued estimates for Dogwood Therapeutics’ Q4 2024 earnings at ($1.49) EPS, FY2024 earnings at ($5.71) EPS, FY2025 earnings at ($4.57) EPS and FY2026 earnings at ($1.90) EPS.
Dogwood Therapeutics Stock Up 21.0 %
NASDAQ DWTX opened at $4.43 on Wednesday. Dogwood Therapeutics has a 52 week low of $2.50 and a 52 week high of $26.00. The stock has a market cap of $4.96 million, a PE ratio of -0.74 and a beta of 1.58.
Dogwood Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Recommended Stories
- Five stocks we like better than Dogwood Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- 3 REITs to Buy and Hold for the Long Term
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- How to Most Effectively Use the MarketBeat Earnings Screener
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
